e-Therapeutics' lead assets, ETS2101 (cancer) and ETS6103 (major depressive disorders), are progressing through clinical trials as planned. ETS2101 has completed three Phase Ia trials and has started Phase Ib in HCC and pancreatic cancer. The Phase IIb data readout of ETS6103, expected in Q116, could trigger a licensing deal. Meanwhile, significant progress has been made in the preclinical discovery projects. Initial areas of focus are cancer immunotherapy and therapeutic resistance rescue wi
12 Oct 2015
Discovery platform coming to the fore
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Discovery platform coming to the fore
e-Therapeutics plc (ETX:LON) | 10.0 0 (-2.5%) | Mkt Cap: 58.1m
- Published:
12 Oct 2015 - Author:
- Pages:
e-Therapeutics' lead assets, ETS2101 (cancer) and ETS6103 (major depressive disorders), are progressing through clinical trials as planned. ETS2101 has completed three Phase Ia trials and has started Phase Ib in HCC and pancreatic cancer. The Phase IIb data readout of ETS6103, expected in Q116, could trigger a licensing deal. Meanwhile, significant progress has been made in the preclinical discovery projects. Initial areas of focus are cancer immunotherapy and therapeutic resistance rescue wi